13060-14-5
Chemical Structure
Yangambin
- CAS No.: 13060-14-5
- Formula:C24H30O8
- Molecular Weight:446.49
IUPAC Name: (1S,3aR,4S,6aR)-1,4-bis(3,4,5-trimethoxyphenyl)tetrahydro-1H,3H-furo[3,4-c]furan
InChIKey: HRLFUIXSXUASEX-RZTYQLBFSA-N
SMILES: COC1=C(OC)C(OC)=CC([C@H]2OC[C@]3([H])[C@@H](C4=CC(OC)=C(OC)C(OC)=C4)OC[C@@]32[H])=C1
Biological Activity: Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Yangambin | 98.27% | Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Serra MF, et al. Anti-allergic properties of the natural PAF antagonist yangambin. Planta Med. 1997;63(3):207-212. [Content Brief]
- [2]. de Sousa FC, et al. Central nervous system activity of yangambin from Ocotea duckei Vattimo (Lauraceae) in mice. Phytother Res. 2005;19(4):282-286. [Content Brief]
- [3]. Rebouças-Silva J, et al. In vitro leishmanicidal effect of Yangambin and Epi-yangambin lignans isolated from Ocotea fasciculata (Nees) Mez. Front Cell Infect Microbiol. 2023 Jan 10;12:1045732. [Content Brief]
- [4]. Castro-Faria-Neto HC, et al. Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies. Planta Med. 1995;61(2):106-112. [Content Brief]
- [5]. Araújo IG, et al. Calcium influx inhibition is involved in the hypotensive and vasorelaxant effects induced by yangambin. Molecules. 2014;19(5):6863-6876. Published 2014 May 23. [Content Brief]
- [6]. Park R, et al. Tetrahydrofurofuranoid Lignans, Eudesmin, Fargesin, Epimagnolin A, Magnolin, and Yangambin Inhibit UDP-Glucuronosyltransferase 1A1 and 1A3 Activities in Human Liver Microsomes. Pharmaceutics. 2021 Feb 1;13(2):187. [Content Brief]
